Abstract
Alpha 1-antitrypsin (α1AT) deficiency disease is one of the more common hereditary disorders that affects the liver and lung. The liver disease of α1AT deficiency is generally thought to be caused by the accumulation of an abnormal α1AT protein in hepatocytes, whereas the lung disease is thought to be due to a relative lack of the normal protein in the circulation. Therefore, one possible approach to prevent and treat α1AT disease is to both inhibit the expression of the mutated α1AT gene, and to provide a means of synthesizing the normal protein. To do this, we designed specific hammerhead ribozymes that were capable of cleaving the α1AT mRNA at specific sites, and constructed a modified α1AT cDNA not susceptible to ribozyme cleavage. Ribozymes were effective in inhibiting α1AT expression in a human hepatoma cell line using a newly developed simian virus (SV40) vector system. In addition, the hepatoma cell line was stably transduced with a modified α1AT cDNA that was capable of producing wild-type α1AT protein, but was not cleaved by the ribozyme that decreased endogenous α1AT expression. These results suggest that ribozymes can be employed for the specific inhibition for an abnormal α1AT gene product, the first step in designing a gene therapy for the disease. The findings also suggest that the novel SV40-derived vector may represent a fundamental improvement in the gene therapeutic armarmentarium.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Crystal R et al. The α1-antitrypsin gene and its mutations: clinical consequences and strategies for therapy Chest 1989 95: 196–208
Long G et al. Complete sequence of the cDNA for human α1 antitrypsin and the gene for the S variant J Biochem 1984 23: 4828–4837
Hubbard R, Crystal R . α1-Antitrypsin deficiency Am J Med 1988 85: 52–62
Crystal RG . The α1 antitrypsin gene and its deficiency states Trends Genet 1989 5: 411–417
Errickson S, Carlson S, Velez R . Risk of cirrhosis and primary liver cancer in α1-antitrypsin deficiency New Engl J Med 1986 314: 736–739
Sifers R et al. A frameshift mutation results in a truncated α1-antitrypsin that is retained within the rough endoplasmic reticulum J Biol Chem 1988 263: 7330–7335
Alino S et al. In vivo delivery of human α1-antitrypsin gene to mouse hepatocytes by liposomes Biochem Biophys Res Comm 1993 192: 174–181
Jaffe H et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver Nat Genet 1992 1: 372–378
Kay M et al. Expression of human α1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes Proc Natl Acad Sci USA 1992 89: 372–378
Feng M et al. Neoplastic reversion accomplished by high efficiency adenovirus-mediated delivery of an anti-ras ribozyme Cancer Res 1995 55: 2024–2028
Kobayashi H, Dorai T, Holland JF, Ohnuma T . Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1(PGY1) ribozyme Cancer Res 1994 54: 1271–1275
Sarvar N et al. Ribozymes as potential anti-HIV-1 therapeutic agents Science 1990 247: 1222–1225
Scanlon KJ et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein Proc Natl Acad Sci USA 1991 88: 10591–10595
Shore SK, Nabissa PM, Reddy EP . Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity Oncogene 1993 8: 3183–3188
Yu M et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 1993 90: 6340–6344
Strayer DS . SV40 as an effective gene transfer vector in vivo J Biol Chem 1996 27: 24741–24746
Strayer DS, Milano J . SV40 mediates stable gene transfer in vivo Gene Therapy 1996 3: 581–587
Ozaki I et al. Ribozyme-mediated specific gene replacement of the α1-antitrypsin ribozyme in a human hepatoma cell line J Hepatol (submitted)
Bartolome J, Madejon A, Carreno V . Ribozymes: structure, characteristics and use as potential antiviral agents J Hepatol 1995 22: 57–64
Offensperger WB, Blum HE, Gerok W . Molecular therapeutic strategies in hepatitis B virus infection Clin Invest 1994 72: 737–741
Sczakiel G, Nedbal W . The potential of ribozymes as antiviral agents Trends Microbiol 1995 3: 213–217
Shillitoe EJ, Kamath P, Chen Z . Papillomaviruses as targets for cancer gene therapy Cancer Gene Ther 1994 1: 193–204
Larsson S et al. Reduced beta 2-macroglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme Nucleic Acids Res 1994 22: 2242–2248
Lieber A, Kay MA . Adenovirus-mediated expression of ribozymes in mice J Virol 1996 70: 3153–3158
Thompson JD et al. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter Nucleic Acids Res 1995 23: 2259–2268
Sullinger BA et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication Mol Cell Biol 1990 10: 6512–6523
Kirschmeier PT et al. Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences DNA 1988 7: 219–225
Wilkinson DA et al. Autonomous expression of RTUL-H endogenous retrovirus-like elements in human cells J Virol 1990 64: 2157–2167
Ozaki I et al. Application of ribozymes for gene therapy of liver disease in α1-antitrypsin deficiency In: Molecular Diagnosis and Gene Therapy Kluwer Academic: Dordrecht 1996 pp 106–115
Scharfmann R, Axelrod JH, Verma IM . Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblasts implants Proc Natl Acad Sci USA 1991 88: 4626–4630
Strayer DS et al. Titering replication-defective virus for use in gene transfer Biotechniques 1997 22: 447–449
Rosenberg BH, Deutsch JF, Ungers GE . Growth and purification of SV40 virus for biochemical studies J Virol Meth 1981 3: 167–176
Chomczynski P, Sacchi N . Single-step method of RNA extraction by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 1987 162: 156–159
Frizell E et al. Expression of SPARC in normal and fibrotic livers Hepatology 1995 21: 847–854
Yun-Tso J et al. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene Nucleic Acids Res 1985 13: 2485–2502
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zern, M., Ozaki, I., Duan, L. et al. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther 6, 114–120 (1999). https://doi.org/10.1038/sj.gt.3300793
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300793
Keywords
This article is cited by
-
Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles
Molecular Therapy (2012)
-
In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA
Laboratory Investigation (2007)
-
HIV-1 proprotein processing as a target for gene therapy
Gene Therapy (2003)
-
Exploiting hepatitis C virus activation of NFκB to deliver HCV-responsive expression of interferons α and γ
Gene Therapy (2003)
-
Conditional expression of α1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV
Gene Therapy (2003)